Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NovaCardia, Inc.
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Furosemide; Rolofylline

Criteria

Inclusion Criteria:

• Stable congestive heart failure

• Impaired renal function

• Taking oral loop diuretic

Exclusion Criteria:

• Acutely decompensated (unstable) and end stage heart failure

• Diuretics other than loop diuretics

• Pregnant or nursing

• Inability to follow instructions

• Participation in another clinical trial within past 30 days